Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614304 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL22581595 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL18614199 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119459 | 0.98 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29709621 | 0.98 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL23722984 | 0.98 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119456 | 0.98 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119686 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118173 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL178739 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | FAP, FIBP, FGF23 | MDM4 2377/4885TP53 273/4885CASP3 1420/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | MDM4 1577/4885TP53 11/4885CASP3 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.